ERT appoints Klaus Besier to board of directors

Brings more than 30 years of experience in software to role

eResearch Technology (ERT), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, has appointed Klaus Besier its board of directors.

Besier brings to Philadelphia, US-based ERT more than 30 years of executive experience in leading software technology companies. He was formerly president and chief executive of SAP America and is credited with driving its growth in North and South America, Australia and New Zealand from US$50m to US$1bn in revenues in less than five years.

He also held the same position at Firepond and at Neoware.

Most recently, Besier served as ceo of Pramata. He is currently ceo of RES Software and a member of the board of directors of ICG Commerce.

‘As the industry leader in cardiac safety, respiratory and multi-mode ePRO solutions for the clinical trial market, ERT has provided unparalleled scientific and regulatory leadership to the global health care industry,’ said Besier. ‘I am delighted to be part of a strong management team consisting of individuals who share a long industry track record.’

You may also like

Regulatory

Exco InTouch launches Gather and redefines the use of mobile technology in clinical trials

New product suite supports patients, sites and sponsors throughout the clinical journey
Digital

Exco InTouch and AstraZeneca collaborate on mHealth programme

Uses mobile phone and web-based technologies to improve condition management for COPD patients
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now